肾细胞癌中免疫检查点抑制剂暴露后的免疫治疗策略:综述
本综述评估了既往接受过免疫治疗的晚期肾细胞癌患者的治疗策略。来自其他恶性肿瘤的证据提示免疫检查点抑制剂再挑战可能有效。回顾性数据提示免疫治疗再挑战疗效有限,但大型3期试验未能证明显著的无进展生存和总生存获益;目前无随机证据支持在既往接受免疫治疗的患者中使用靶向常规免疫检查点的药物。
要点
- 回顾性数据提示免疫检查点抑制剂再挑战治疗疗效有限。
- 大型3期试验未能证明显著的无进展生存和总生存获益。
- 目前无随机证据支持既往接受免疫治疗的患者使用靶向常规免疫检查点的药物。
核心结论
- 回顾性数据提示免疫检查点抑制剂再挑战治疗疗效有限,但大型3期试验未能证明显著的无进展生存和总生存获益。
- 目前无随机证据支持在既往接受过免疫治疗的肾细胞癌患者中使用靶向常规免疫检查点的药物。
研究设计与样本
- 本综述评估了既往暴露于免疫治疗的晚期肾细胞癌患者的不同治疗策略。
- 综述呈现了包括回顾性、前瞻性和随机临床试验在内的现有最重要数据。
主要发现
- 来自其他恶性肿瘤的证据提示免疫检查点抑制剂再挑战可能有效。
- 回顾性数据提示免疫治疗再挑战治疗疗效有限。
- 大型3期试验未能证明显著的无进展生存和总生存获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Immune checkpoint inhibitors have transformed the treatment landscape for metastatic renal cell carcinoma; however, the failure of first-line therapeutic strategies remains a considerable challenge. Currently, clinicians face various issues, such as managing cases in patients who progress during treatment or relapse after adjuvant immunotherapy. OBSERVATIONS: This review evaluates different strategies for treating patients with advanced kidney cancer previously exposed to immunotherapy. Evidence from other malignant neoplasms suggests potential effectiveness for rechallenging with immune checkpoint inhibitors. The most important available data are presented, including retrospective, prospective, and randomized clinical trials, to explore the role of immunotherapy in patients with renal cell carcinoma who have experienced prior failure of immune checkpoint inhibitors. CONCLUSIONS AND RELEVANCE: Although retrospective data suggest modest effectiveness of an immunotherapy rechallenge treatment, larger phase 3 trials failed to demonstrate substantial benefit in progression-free survival and overall survival. Currently, no randomized evidence supports the use of agents targeting conventional immune checkpoints in patients with renal cell carcinoma who have previously received immunotherapy.
引用
- Giudice GC, Beckermann KE, Siqueira Do Amaral P, et al. Immunotherapy Strategies After Immune Checkpoint Inhibitor Exposure in Renal Cell Carcinoma: A Review. JAMA Oncol. 2025. PMID: 40146173. doi:10.1001/jamaoncol.2025.0017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。